2023 Regular Session ENROLLED SENATE RESOLUTION NO. 101 BY SENATOR BOUDREAUX A RESOLUTION To urge and request the Centers for Disease Control and Prevention to include monoclonal antibodies for respiratory syncytial virus (RSV) within the federal Vaccines for Children program. WHEREAS, RSV is a highly transmissible, seasonal virus which may have severe and unpredictable outcomes for infants, including hospitalization; and WHEREAS, nearly all children will be infected with RSV by the age of two, and most infants requiring hospitalization were previously healthy and born at term; and WHEREAS, RSV is the leading cause of hospitalization among infants in the United States; and WHEREAS, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia (infection of the lungs) in children younger than one year of age in the United States; and WHEREAS, the most recent RSV season has resulted in significant morbidity and increased mortality; and WHEREAS, RSV disproportionally affects infants with Medicaid coverage and Native Americans; and WHEREAS, the Vaccines for Children (VFC) program is a federally funded program that provides vaccines at no cost to children who might not otherwise be vaccinated because of an inability to pay; and WHEREAS, VFC coverage is critical to ensure equity and ensure high uptake to have the greatest impact on disease burden. THEREFORE, BE IT RESOLVED that the Senate of the Legislature of Louisiana does hereby urge and request the Centers for Disease Control and Prevention to include monoclonal antibodies for RSV within the federal Vaccines for Children program. PRESIDENT OF THE SENATE Page 1 of 1